Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.
Conditions
Interventions
GBT021601
Locations
4
United States
ICON Early Phase Services, LLC
San Antonio, Texas, United States
Harry Perkins Institute of Medical Research
Nedlands, Western Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Oxford Compounding
North Perth, Western Australia, Australia
Start Date
December 9, 2020
Primary Completion Date
November 2, 2022
Completion Date
February 7, 2023
Last Updated
July 25, 2023
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions